Profile: Targacept Inc (TRGT.OQ)
5.05USD
1:04pm EDT
$-0.03 (-0.59%)
$5.08
$5.05
$5.07
$5.02
9,839
59,325
$5.77
$3.86
Targacept, Inc., incorporated in 1997, is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs). As of December 31, 2011, the Company had multiple clinical-stage product candidates and preclinical programs in areas. The Company's drug discovery activities utilize computer-based molecular design methodologies and biological and chemical data for a library of diverse compounds developed and collected. The Company refers to these technologies collectively as Pentad. Its clinical-stage product candidates include TC-5214, TC-5619, TC-6987, AZD3480 (TC-1734), AZD1446 (TC-6683), TC-6499 and TC-6987.
TC-5214
TC-5214 is a nicotinic channel modulator that is in development as a treatment for depressive disorder. The Company is co-developing TC-5214 under its TC-5214 agreement with AstraZeneca. The clinical program for TC-5214 includes development both as an adjunct, or add-on, therapy and as a switch monotherapy, The Company and AstraZeneca refer to the Phase III program as the RENAISSANCE Program. The RENAISSANCE Program includes four multi-center, double blind, parallel group clinical trials. Both of the flexible dose trials in the RENAISSANCE Program were completed during the year ended December 31, 2011. The Company and AstraZeneca are also conducting a Phase IIb clinical trial of TC-5214 as a switch monotherapy. In addition to the RENAISSANCE Program, the Company and AstraZeneca are conducting multiple Phase I clinical trials of TC-5214, including a corrected Q-T interval (QTc) study.
TC-5619
TC-5619 is a small molecule that modulates the activity of the a7 NNR. As of December 31, 2011, the Company was conducting a Phase 2b clinical trial of TC-5619 in negative symptoms and cognitive dysfunction in schizophrenia. As of December 31, 2011, the Company was also conducting a Phase II clinical trial of TC-5619 in attention deficit/hyperactivity disorder (ADHDi) in adults. In addition to the Company's ongoing development, the Company is evaluating Phase II clinical development of TC-5619 in Alzheimer's disease. As of December 31, 2011, the Company had completed a Phase II clinical trial of TC-5619 in cognitive dysfunction in schizophrenia, and had also completed a Phase II clinical trial of TC-5619 in adults with ADHD.
AZD3480 (TC-1734)
AZD3480 (TC-1734) is a small molecule that modulates the activity of the a4ß2 NNR. The Company or AstraZeneca have conducted several clinical studies of AZD3480 in various cognitive disorders. As of December 31, 2011, the Company was conducting a Phase IIb clinical trial of AZD3480 as a treatment for mild to moderate Alzheimer's disease. The Company's ongoing study is the second clinical trial of AZD3480 in mild to moderate Alzheimer's disease.In addition to the previous trial in Alzheimer's disease, the Company or AstraZeneca have completed Phase II clinical trials of AZD3480 in various other indications as of December 31, 2011.
AZD1446 (TC-6683)
AZD1446 (TC-6683) is a small molecule that modulates the activity of the a4ß2 NNR. AstraZeneca has completed various early-stage clinical studies of AZD1446.
TC-6987
TC-6987 is a small molecule that modulates the activity of the a7 NNR. As of December 31, 2011, the Company was conducting two separate Phase II clinical trials of TC-6987. One of the ongoing studies is in asthma and the other is in Type II diabetes.The Company's ongoing Phase II clinical trial in asthma is a multicenter, double blind, placebo controlled, parallel group study being conducted in the United States. There are 94 adult subjects with asthma mild to moderate in 70 enrolled in the study. There are 112 adult subjects with Type II diabetes enrolled in the study.
TC-6499
TC-6499 is a small molecule that modulates the activity of the a4ß2 and a3ß4 NNRs. The a3ß4 NNR is located in the gastrointestinal tract. During 2011, the Company completed an exploratory four-week study of TC-6499.
The Company Roche, Abbott Laboratories, Eli Lilly, Sanofi-Aventis, Johnson & Johnson, Novartis, NeuroSearch A/S, Solvay, Servier, CoMentis, EnVivo Pharmaceuticals, Galantos Pharma, Proximagen, Psychogenics, Suven, Asmacure, Neuroderm, AstraZeneca, Bristol-Myers Squibb/Otsuka, GlaxoSmithKline, Pfizer, Forest Laboratories, Wyeth, Shire, Merck, Cornerstone Therapeutics and Eisai.
Company Address
Targacept Inc
Suite 1510, 100 North Main Stree
WINSTON-SALEM NC 27101
P: +1336.4802100
F: +1336.4802107
Company Web Links
| Name | Compensation |
|---|---|
Mark Skaletsky |
-- |
Stephen Hill |
-- |
Alan Musso |
1,145,620 |
Peter Zorn |
1,120,620 |
Merouane Bencherif |
438,644 |

